Virginia 2026 Regular Session

Virginia Senate Bill SB418

Introduced
1/13/26  
Refer
1/13/26  
Report Pass
2/5/26  
Engrossed
2/9/26  
Engrossed
2/9/26  
Refer
2/13/26  
Report Pass
2/24/26  
Enrolled
3/4/26  
Chaptered
4/13/26  

Caption

Therapeutic interchange; authorizes pharmacists to perform, adaptation of prescriptions.

Impact

The passage of SB418 will amend existing laws in Virginia, particularly impacting the regulatory framework governing pharmacy practices and prescription medications. By empowering pharmacists to adapt prescriptions to more cost-effective or available options, the bill aims to improve medication management and healthcare delivery. This change is anticipated to streamline processes within pharmacies, facilitate access to essential medications, and potentially reduce the financial burden on patients and healthcare systems alike.

Summary

SB418, also known as the Therapeutic Interchange and Adaptation Bill, enables pharmacists in Virginia to perform therapeutic interchanges by substituting prescribed medications with alternatives within the same therapeutic class. This provision is designed to enhance patient care while managing costs effectively. A pharmacist is permitted to make substitutions when such changes are cost-neutral or beneficial in a situation of drug shortage, thus addressing both patient accessibility and economic considerations.

Sentiment

General sentiment surrounding SB418 appears to be supportive, especially among healthcare professionals and patient advocates who recognize the bill's potential to alleviate medication shortages and improve patient care. However, there may be reservations among some healthcare providers regarding the implications of allowing pharmacists more discretion in managing patient prescriptions. The balance between cost-saving measures and maintaining the integrity of patient care protocols is central to the discourse surrounding the bill.

Contention

Notable points of contention may arise from concerns about the appropriateness of pharmacists acting independently in changing prescriptions without direct input from prescribing physicians. Opponents may argue that this could lead to miscommunication or a lapse in individualized care. Furthermore, stipulations concerning the notification of prescribers within 24 hours of a substitution, while intended to maintain communication, may raise questions about procedural robustness and the responsibilities of pharmacists in ensuring patient understanding of their medication changes.

Companion Bills

No companion bills found.

Previously Filed As

VA SB745

Therapeutic interchange; Bd. of Pharmacy to convene work group to review authority of pharmacists.

VA HB2378

Therapeutically equivalent drug products; provisions for return of outdated drugs.

VA HB1956

Provider contracts; pharmacies allowed to refuse to fill certain prescriptions.

VA HB1582

Pharmacists; collaborative agreements, drug therapy.

VA HB2329

Health insurance; prescription drug formularies.

VA HB2307

Prescription Monitoring Program; requirements of practitioners, pharmacy technicians, training prog.

VA HB2473

Long-acting injectable or extended-release prescription drugs; correctional facilities.

VA SB1367

Long-acting injectable or extended-release prescription drugs; correctional facilities.

VA HB2107

Health insurance; pharmacies, freedom of choice, delivery of prescription drugs, penalties.

VA HB1898

Optometry; TPA-Formulary; TPA-Formulary Committee; dissolution.

Similar Bills

No similar bills found.